Completion of Nominated Adviser due diligence

RNS Number : 6865T

Ondine Biomedical Inc.

26 July 2022

 

26 July 2022                                           

Ondine Biomedical Inc.

("Ondine Biomedical", "Ondine" or the "Company")

Completion of Nominated Adviser due diligence

Ondine Biomedical Inc. (AIM: OBI) announces that Strand Hanson Limited, appointed as the Company's Nominated Adviser on 27 April 2022, has confirmed completion of its due diligence.

Pursuant to Schedule 2(g)(ii) of the AIM Rules for Companies, the following disclosures are required:

Director	Current directorships
Carolyn Cross	12673011 Canada Inc.
Nicolas Loebel	Advanced Photodynamic Technologies Inc. Axcess Medical Inc. Ondine Research Laboratories Ltd

For more information, please visit: www.ondinebio.com or contact: 

Ondine Biomedical Inc. 

Carolyn Cross, CEO   +001 (1) 604 669 0555

Strand Hanson Limited (Nominated and Financial Adviser)

Richard Johnson, James Harris, James Dance                                                               [phone]

Arden Partners plc (Broker)

Ruari McGirr    [phone]

Vane Percy & Roberts (Media Contact)

Simon Vane Percy, Amanda Bernard                                                                              [phone]

 

END

 

 

MSCBKPBKDBKBBOB